4CPS-084 Identification of patient candidates to switch from tenofovir/emtricitabine to abacavir/lamivudine antiretroviral therapy: economic saving

BACKGROUND: The increase in life expectancy in patients receiving antiretroviral therapy (ART) and the incorporation of new drugs into the market, significantly increases the cost associated with the treatment of human immunodeficiency virus (HIV). Therefore, it would be a convenient optimisation of...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Eur J Hosp Pharm
Egile Nagusiak: Moreno-Garcia, M, Castellano-Herrador, JJ, Madrid-Gonzalez, M, Ramis-Riera, X, Santos-Pérez, M, Prada-Lobato, J, Rodriguez-Barbero, J
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Group 2018
Gaiak:
Section 4: Clinical pharmacy services
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535446/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.175
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak